Drug Design Development and Therapy · 2018 · 17 citations · 15 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyDosage Form DesignPharmaceutical FormulationCoated Dosage FormsDrug DispositionTablet DesignTablet FormulationDrug Formulation ComparisonGeometric Mean RatioOrodispersible TabletsPharmacokinetic Parameter AnalysisPharmacokinetic ParametersPlasma Concentration - Time ProfileTadalafil TherapyTherapy Tolerability
BACKGROUND: An orodispersible film (ODF) of tadalafil may provide increased convenience for erectile dysfunction (ED) patients as compared to conventional tablet formulations. In this study, we aimed to compare the pharmacokinetic, safety, and tolerability profiles of a newly developed ODF formulation of tadalafil to those of a film-coated tablet (FCT) of tadalafil. MATERIALS AND METHODS: This study was conducted in healthy male subjects using an open-label, randomized sequence, two-period, two-formulation, single-dose, crossover design. The subjects were randomly assigned to one of two sequences of the two formulations: both the test drug (ODF) and the reference drug (FCT) contained 20 mg of tadalafil. Blood samples were collected up to 72 h after administration. Plasma concentrations of tadalafil were analyzed using liquid chromatography-tandem mass spectrometry. Geometric mean ratios (GMRs) of the ODF to FCT formulations and their 90% CIs for the pharmacokinetic parameters were estimated. Safety and tolerability were assessed throughout the study. RESULTS: Forty healthy male subjects were enrolled, and 36 of these completed the study. The GMRs (90% CIs) of the maximum plasma concentration and the area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration for tadalafil were 0.927 (0.882-0.974) and 0.972 (0.918-1.029), respectively. Both ODF and FCT formulations were well tolerated, and no clinically significant changes from the baseline were observed after dosing. CONCLUSION: The pharmacokinetics of the tadalafil ODF formulation did not differ significantly from those of the FCT formulation. Furthermore, the safety and tolerability profiles of the ODF formulation were comparable to those of the FCT formulation. Therefore, this tadalafil ODF formulation offers a convenient treatment option for patients with erectile dysfunction.
15
NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence
JAMA · 1993 · 843 citations
Thin films as an emerging platform for drug delivery
Sandeep Karki, Hyeongmin Kim, Seon-Jeong Na et al. · Asian Journal of Pharmaceutical Sciences · 2016 · 534 citations · Full text